All In Biotech

Drug Trial Radar · NCT07082842

Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF

A Multicenter, Parallel, Randomized, Placebo (Double-blind) and Pirfenidone (Open-label) Controlled Phase III Clinical Trial Evaluating the Efficacy and Safety of HEC585 Tablets in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Last checked: Nov 19, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 472 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

472

Planned (sponsor's estimate)

Start

Oct 27, 2025

Primary completion

Jan 15, 2031

Study completion Feb 15, 2032

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, parallel, randomized, placebo (double-blind) and pirfenidone (open-label) controlled Phase III clinical trial to evaluate the efficacy and safety of HEC585 in patients with idiopathic pulmonary fibrosis (IPF)

Conditions

  • Idiopathic Pulmonary Fibrosis (IPF)

Interventions

  • HEC585Drug

    HEC585 tablet, taken once daily

  • PlaceboDrug

    HEC585 Simulation Board, taken once daily

  • PirfenidoneDrug

    Pirfenidone, taken three times a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in FVC from baseline at 52 weeks (mL)Time frame: 52week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.